Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.

@article{Swick2017CotargetingMA,
  title={Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.},
  author={Adam D Swick and Prashanth J Prabakaran and Margot C Miller and Amal M Javaid and Michael M. Fisher and Emmanuel Sampene and Irene M. Ong and Rong Hu and Mari Iida and Kwangok P. Nickel and Justine Yang Bruce and Deric L Wheeler and Randall J. Kimple},
  journal={Molecular cancer therapeutics},
  year={2017},
  volume={16 7},
  pages={
          1257-1268
        }
}
Head and neck squamous cell carcinomas (HNSCC) are frequently altered along the PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of compounds targeting this pathway as monotherapy has been underwhelming in initial clinical trials, and identification of predictive biomarkers remains challenging. To investigate mTORC-specific inhibition, we tested catalytic mTORC (AZD8055) and PI3K/mTORC (NVP-BEZ-235) inhibitors ± cetuximab in a panel of HNSCC cell lines and patient… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS